logo
Twitter
Discord
Email
logo
Boston Scientific Corporation

Boston Scientific Corporation

NYSE•BSX
CEO: Mr. Michael F. Mahoney
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1992-05-19
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Contact Information
300 Boston Scientific Way, Marlborough, MA, 01752-1234, United States
508-683-4000
www.bostonscientific.com
Market Cap
$141.96B
P/E (TTM)
51.1
36.3
Dividend Yield
--
52W High
$109.50
52W Low
$85.98
52W Range
42%
Rank39Top 29.7%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$5.07B+20.34%
4-Quarter Trend

EPS

$0.51+60.13%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Q3 Sales Growth Net sales reached $5.065B USD in Q3 2025, marking a 20.3% increase, driven by 19.4% operational growth across segments.
Nine Month Net Income Soars Net income attributable to stockholders for nine months totaled $2.226B USD, significantly up from $1.288B USD prior year.
Operating Cash Flow Jumps Cash provided by operating activities for nine months increased $1.191B USD to $3.170B USD due to higher sales.
Key Segment Sales Expansion Cardiology segment sales grew 24.0% in Q3 2025, led by Electrophysiology and WATCHMAN adoption across the portfolio.

Risk Factors

Acquisition Contingent Liability Contingent consideration liability stands at $378M USD as of September 30, 2025, reflecting recent business combinations activity.
Ongoing Litigation Exposure Product liability and IP litigation remain ongoing; adverse outcomes could materially impact operations, liquidity, and financial position.
ACURATE Platform Discontinuation Discontinuation of ACURATE systems resulted in approximately $90M USD pre-tax restructuring charges recognized in nine months 2025.
Regulatory Environment Uncertainty Business faces risks from evolving global regulatory enforcement, including EU MDR and potential changes in trade policies.

Outlook

Nalu Medical Acquisition Planned Definitive agreement signed to acquire Nalu Medical for expected upfront cash payment of approximately $533M USD, closing H1 2026.
Continued Electrophysiology Focus Growth driven by Farapulse PFA System adoption in Electrophysiology and continued focus on core portfolio strength.
ERP Implementation Progress Multi-year ERP system implementation is progressing, with significant transition completed for Europe, Middle East, and Africa operations.
Strong Liquidity Position Available liquidity remains strong at $2.750B USD via the 2021 Revolving Credit Facility; no commercial paper outstanding.

Peer Comparison

Revenue (TTM)

McKesson CorporationMCK
$387.09B
+17.2%
Pfizer Inc.PFE
$62.79B
+3.9%
SanofiSNY
$46.51B
-11.2%

Gross Margin (Latest Quarter)

Gilead Sciences, Inc.GILD
79.8%
+0.7pp
Pfizer Inc.PFE
74.9%
+14.1pp
SanofiSNY
74.1%
+2.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ABT$216.82B15.628.2%15.4%
ISRG$205.55B75.016.1%0.0%
AMGN$177.50B25.696.2%60.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.6%
Moderate Growth
4Q Net Income CAGR
10.1%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 4, 2026
|
EPS:$0.78
|
Revenue:$5.29B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 3, 2025|
    Revenue: $5.07B+20.3%
    |
    EPS: $0.51+60.1%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 1, 2025|
    Revenue: $5.06B+22.8%
    |
    EPS: $0.54+145.1%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $4.66B+20.9%
    |
    EPS: $0.46+35.4%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 18, 2025|
    Revenue: $16.75B+17.6%
    |
    EPS: $1.26+16.6%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 1, 2024|
    Revenue: $4.21B+19.3%
    |
    EPS: $0.32-7.6%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $4.12B+14.5%
    |
    EPS: $0.22+22.1%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 1, 2024|
    Revenue: $3.86B+13.8%
    |
    EPS: $0.34+61.4%
    Miss
  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $14.24B+12.3%
    |
    EPS: $1.08+140.8%
    Beat